피하 면역글로불린 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The subcutaneous immunoglobulin market is valued at USD 10.53 billion in 2025 and is projected to reach USD 15.73 billion by 2030, advancing at an 8.35% CAGR.

Patient preference for self-managed therapy, improved infusion technologies, and payer support for home care together sustain a demand curve that remains comfortably above global plasma-collection capacity. Primary immunodeficiency continues to anchor demand because earlier diagnosis broadens the treated population, while neurological and hematologic conditions steadily push beyond niche status. Facilitated formulations extend the addressable base by compressing a month of therapy into one session, a feature that improves adherence and reduces indirect costs. Geographically, North America retains consumption leadership, yet the Asia-Pacific trajectory rises more steeply as Japan, China, and Australia clear new products and streamline reimbursement pathways. Manufacturers respond to chronic plasma scarcity with yield-enhancement processes, fractionation expansion, and partnerships that shorten supply chains.

Global Subcutaneous Immunoglobulin Market Trends and Insights

Growing Prevalence of Primary Immunodeficiency Disorders Drives Market Expansion

Improved screening algorithms embedded in large electronic-health-record systems now identify 6 in 10,000 individuals with inborn errors of immunity, well above earlier assumptions. More accurate epidemiology means physicians prescribe replacement therapy earlier, which lengthens a patient's lifetime exposure to subcutaneous products. Hospital data place the average cost of admission for severe infections at USD 122,739, a level that persuades insurers to fund preventive immunoglobulin therapy. Parallel discoveries of immune deficits in Down syndrome and other syndromic conditions widen the treated population. COVID-19 experience further supports prophylactic IgG use for vulnerable groups as they transition from pandemic to endemic risk. Together these factors elevate baseline demand and stabilize year-on-year volume growth for the subcutaneous immunoglobulin market.

Patient Preference Accelerates IVIG-to-SCIG Migration

Survey data show that 82% of patients prefer subcutaneous delivery and 84% favor home administration, citing autonomy and reduced travel burden. Real-world studies confirm equal efficacy alongside fewer systemic reactions, particularly in chronic neuromuscular conditions. Health-economic analyses reveal that nurses spend 35 hours per patient annually on subcutaneous support versus significantly higher labor for intravenous regimens. Pre-filled syringes, manual push options, and small portable pumps remove the technical hurdles that once confined therapy to infusion suites. These combined conveniences channel a steady stream of new starters directly into the subcutaneous immunoglobulin market.

Global Plasma Supply Constraints Challenge Market Growth Sustainability

Every liter of plasma requires 7-12 months of fractionation before a dose reaches the patient, so even modest demand increments strain inventories. Governments act: the United Kingdom moved from 0% to 25% plasma self-sufficiency by 2025 and targets 30-35% by 2031. Manufacturers upgrade processes, and ADMA Biologics filed for a 20% yield enhancement that uses optimized chromatography and virus-filtration steps. Yet collection policy changes in major donor countries still cap growth, and regional shortfalls appear first in developing economies with limited fractionation capacity. The subcutaneous immunoglobulin market therefore relies on continuous innovation to stretch each liter of plasma further.

Other drivers and restraints analyzed in the detailed report include:

1. Aging Demographics and Chronic Disease Burden Expand Treatment Population
2. Hyaluronidase-Facilitated Therapy Transforms Administration Paradigms
3. FcRn-Inhibitor Biologics Emerge as Competitive Threat

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Primary immunodeficiency held 58.67% revenue in 2024 and is advancing at an 8.96% CAGR, underpinning the largest slice of the subcutaneous immunoglobulin market. Greater physician awareness, newborn screening pilots, and genomic testing converge to catch patients earlier, which extends therapy lifespan. Secondary immunodeficiency linked to chemotherapy, stem-cell transplant, and antirheumatic medications adds a sizeable cohort that previously relied on hospital IVIG infusions. Neurological applications are rising fastest because chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy have secured guideline support for maintenance dosing. Regulatory clearance of GAMMAGARD LIQUID for CIDP in adults widened payer recognition in 2025. Emerging research on autoimmune encephalitis and stiff-person syndrome further enlarges the potential pool. Precision-medicine initiatives use serum biomarker panels and machine-learning algorithms to stratify patients for subcutaneous versus intravenous routes. This data-guided matching optimizes resource allocation and improves adherence, ensuring that subcutaneous immunoglobulin market growth remains patient-centric.

Segment diversity secures resilience. When plasma scarcity limits volume allocation, manufacturers can redistribute supply toward high-value neurology segments without abandoning core immunodeficiency users. Hospitals, clinics, and home-care services align educational content to reflect the broader indication mix, reducing mis-administration risks. As the treated base widens, real-world evidence networks collect safety, efficacy, and quality-of-life outcomes that feed back into payer dossiers. The feedback loop strengthens contract negotiations and secures formulary placement. Overall, application breadth transforms the subcutaneous immunoglobulin industry into a versatile treatment platform rather than a single-use product line.

Conventional pump infusion retained 48.67% revenue share in 2024 on the strength of entrenched clinical protocols and broad device availability. The method remains favored for children and patients with limited manual dexterity because programmable flow rates minimize infusion-site discomfort. That said, facilitated therapy is scaling quickly at an 8.89% CAGR on the back of hyaluronidase-enabled monthly dosing. Patients who struggled with weekly schedules migrate to one-day-per-month regimens, freeing time and cutting peripheral-catheter consumables. Rapid push, a syringe-driven manual technique, appeals to adults who prefer complete control and minimalist equipment. Comparative studies report non-inferior pharmacokinetics across these techniques, empowering physicians to tailor choices to patient lifestyle.

Device firms innovate in parallel. Wearable on-body injectors under clinical evaluation aim to combine large-volume capacity with discreet form factors. Smart-phone apps log infusion data and push reminders that support adherence. Training modules delivered through augmented reality reduce the initial learning curve and shorten hospital chair time at initiation. Regional practice patterns differ: North America deploys the full menu of techniques, Europe increasingly favors facilitated therapy for adults, and Asia-Pacific installs new-generation pumps capable of high-volume, low-pressure infusions following HYQVIA approval. Collectively, technique diversity underpins sustained depth in the subcutaneous immunoglobulin market.

The Subcutaneous Immunoglobulin Market Report is Segmented by Application (Primary Immunodeficiency Diseases, Secondary Immunodeficiency, and More), Administration Technique (Conventional Pump, Rapid Push, and More), End User (Hospitals, Home Care Settings, and More), and Geography (North America, Europe, and More). Distribution Channel (Hospital Pharmacies, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America owns 41.26% revenue because the United States diagnoses roughly 150,000-200,000 primary immunodeficiency patients and maintains extensive home-infusion benefits under both commercial plans and Medicare. Canada reimburses therapy through provincial formularies and delivers product via hospital or community programs, while Mexico's public-sector tenders are enlarging to include subcutaneous options. Recent Medicare rule changes that reimburse nursing time for home infusions further strengthen adoption. Robust plasma-collection infrastructure, predominantly in the United States, guarantees local supply and buffers international shocks.

Europe positions itself as a self-sufficient producer: the United Kingdom reached 25% domestic plasma self-sufficiency in 2025 and targets 30-35% by 2031. Germany operates the largest fractionation capacity, while France, Italy, and Spain prioritize national plasma-collection drives. The European Medicines Agency supports accelerated reviews for facilitated formulations, as evidenced by HYQVIA's centralized authorization and XEMBIFY's pan-EU label expansion. COVID-19 supply disruptions prompted investment in strategic plasma reserves, synchronizing public health and industrial policy.

Asia-Pacific is the fastest-growing region at 9.12% CAGR, prompted by Japan's 2024 HYQVIA approval and widening reimbursement in urban China. Australia's National Blood Authority supplies product for home administration every two months, embedding subcutaneous formulations into standard care. South Korea leverages its biopharmaceutical ecosystem to push local fractionation projects, while Indonesia attracted inward investment for a first-of-its-kind plasma facility. Challenges include fragmented regulatory frameworks and limited donor networks in emerging markets, but multilateral health-security programs supply technical assistance. The expanding base of qualified fractionation plants lays a durable foundation for the long-term growth of the subcutaneous immunoglobulin market.

1. Takeda Pharmaceuticals
2. CSL Behring
3. Grifols
4. Octapharma
5. Kedrion Biopharma
6. Biotest
7. Bio Products Laboratory (BPL)
8. ADMA Biologics
9. GC Biopharma
10. Sanquin
11. LFB SA
12. Emergent Bio Solutions
13. China Biologic Products
14. Kamada Ltd.
15. Argenx SE
16. Octapharma Plasma Inc. (US)
17. Intas Pharmaceuticals
18. Bioplasma Argentina
19. Bharat Serums & Vaccines
20. Green Cross Health

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Prevalence of Primary Immunodeficiency Disorders (PID)
  • 4.2.2 Shift from IVIG to Home-based SCIG Administration
  • 4.2.3 Aging Population & Rising Chronic Disease Burden
  • 4.2.4 Expanding Reimbursement & Plasma-collection Programs
  • 4.2.5 Hyaluronidase-facilitated High-volume fSCIG Adoption
  • 4.2.6 Decentralised Plasma Sourcing Initiatives
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory & Quality Requirements
  • 4.3.2 High Therapy Cost & Reimbursement Friction
  • 4.3.3 Global Plasma Supply Constraints
  • 4.3.4 Emerging FcRn-inhibitor Biologics as Substitutes
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers/Consumers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value -USD)

• 5.1 By Application
  • 5.1.1 Primary Immunodeficiency
  • 5.1.2 Secondary Immunodeficiency
  • 5.1.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • 5.1.4 Multifocal Motor Neuropathy (MMN)
  • 5.1.5 Other Applications
• 5.2 By Administration Technique
  • 5.2.1 Conventional Pump
  • 5.2.2 Rapid Push
  • 5.2.3 Facilitated (fSCIG) Therapy
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Homecare Settings
  • 5.3.3 Specialty Clinics & Infusion Centers
  • 5.3.4 Others
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Takeda Pharmaceutical Company Limited
  • 6.3.2 CSL Behring
  • 6.3.3 Grifols SA
  • 6.3.4 Octapharma AG
  • 6.3.5 Kedrion SpA
  • 6.3.6 Biotest AG
  • 6.3.7 Bio Products Laboratory (BPL)
  • 6.3.8 ADMA Biologics
  • 6.3.9 GC Pharma
  • 6.3.10 Sanquin
  • 6.3.11 LFB SA
  • 6.3.12 Emergent BioSolutions
  • 6.3.13 China Biologic Products
  • 6.3.14 Kamada Ltd.
  • 6.3.15 Argenx SE
  • 6.3.16 Octapharma Plasma Inc. (US)
  • 6.3.17 Intas Pharmaceuticals
  • 6.3.18 Bioplasma Argentina
  • 6.3.19 Bharat Serums & Vaccines
  • 6.3.20 Green Cross Health

7 Market Opportunities & Future Outlook